{
  "id": "resp_00526f0f50b9f70500693c96c3db988193a73fa7b765fa403b",
  "object": "response",
  "created_at": 1765578435,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_00526f0f50b9f70500693c96c428688193ad54a1a803de1f09",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c96c799648193bbfca5aa692bc645",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Cyclin-K\" degrader drug"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c96c8fd7881938f89edd79913167f",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c96d10d848193b6698cc15c42d8c0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CT7439 trial phase"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c96d296408193a147244ce2db8b25",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c96db9da4819381eb6cac970bbe4c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT06600789 CT7439 locations"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c96ded8c481939d59ef8211b52127",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c96dfea9881939979ef2bdcd989e3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c96e09088819388edb9688a55f832",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c96e2c1b48193b165341b94401cd8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c96e365fc8193a3990ce737471722",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c96e487b08193839f1a5924a8fa1c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "clinicaltrials.gov ct2 show NCT06600789"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c96e7cb908193b23f3c86aaacea3a",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c96f059208193822ebfa1873567ea",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://ichgcp.net/clinical-trials-registry/NCT06600789"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c96f124d481938d0e782b62fd4e82",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c97258c5c8193a9c42b839fe6b47d",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c9726981881938942751ee42d012e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c972753148193aebd5300f13c8687",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c97280a088193b0b1b8bf55da5d53",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_00526f0f50b9f70500693c9729d0b08193bdb114053078391d",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "Sponsor",
        "url": "https://ichgcp.net/clinical-trials-registry/NCT06600789"
      }
    },
    {
      "id": "rs_00526f0f50b9f70500693c972c847c81939c3796347d198e04",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_00526f0f50b9f70500693c974e748c81939a74a36dd426d511",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "{\n  \"validated\": true,\n  \"assets\": [\n    {\n      \"drug_name_code\": \"CT7439 (Cyclin-K Degrader)\",\n      \"sponsor\": \"Carrick Therapeutics Limited\",\n      \"target\": \"CDK12/13; Cyclin-K\",\n      \"modality\": \"CDK12/13 inhibitor / Cyclin-K glue degrader\",\n      \"indication\": \"Solid malignancies / advanced solid tumors (including breast, ovarian and Ewing's sarcoma)\",\n      \"development_stage\": \"Phase 1/2 (recruiting)\",\n      \"geography\": \"United States; United Kingdom\",\n      \"sources\": [\n        \"https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor\",\n        \"https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase\",\n        \"https://ichgcp.net/clinical-trials-registry/NCT06600789\"\n      ]\n    }\n  ],\n  \"rejected_reason\": null\n}"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "xhigh",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 37484,
    "input_tokens_details": {
      "cached_tokens": 4736
    },
    "output_tokens": 9004,
    "output_tokens_details": {
      "reasoning_tokens": 8764
    },
    "total_tokens": 46488
  },
  "user": null,
  "metadata": {}
}